{"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.\n\nFludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi).\n\nSodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).","id":"BG000","title":"Multiple Myeloma (MM) Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.2","value":"64.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Hispanic or Latino"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}